AtriCure CEO says strong revenue growth to continue

SmallCapInvestor.com reporter Jennifer Schonberger is reporting from the 20th Roth Capital Partners Annual OC Growth Stock Conference this week in Dana Point, Calif. The conference features presentations from more than 300 small-cap companies.

AtriCure, Inc. (Nasdaq: ATRC), a developer of surgical devices designed to create precise lesions, or scars, in cardiac and soft tissues for patients with atrial fibrillation (AF), has experienced strong growth year-to-date, but CEO David Drachman said it is about to kick into high gear.

In an interview at the Roth OC Growth Stock Conference in Dana Point, Calif. on Wednesday, Drachman told SmallCapInvestor.com that AtriCure’s growth story will take flight by 2010 and 2011.
 
AtriCure has gone from two platforms in 2005 to eight platforms in 2008.

“If you look at our product platform in 2005, the platform was a bipolar ablation clamp, and a protection tool,” said Drachman. “If you look at the product platform in 2008, it’s a series of open heart bipolar ablation clamps, a series of minimally invasive endoscopic, bipolar ablation clamps, a multifunctional end system that can perform basic electrophysiology like matching cardiac arrhythmia … then there’s a whole platform of enabling technologies.”

By mid-March, the company expects to launch what it calls its cool rails linear ablation tank, which allows more ablation treatments during a minimally invasive approach to obtain more regular outcomes for more permanent patients.

AtriCure’s market share for surgical cardiac ablation devices on the open heart side is approximately 50%, according to Drachman, while its share of the invasive market could be 80% or higher.

---You can read the FULL article when you register (registration is free!) or sign-in to SmallCapInvestor.com---